Home > Annual Financials > JENBURKT PHARMACEUTICALS

JENBURKT PHARMACEUTICALS Financial Statement Analysis
[BOM: 524731]

The Revenues of JENBURKT PHARMACEUTICALS have increased by 10.30% YoY .
The Earnings Per Share (EPS) of JENBURKT PHARMACEUTICALS has increased by 14.78 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

JENBURKT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 524731]

StandaloneMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹137 Cr₹124 Cr₹109 Cr₹119 Cr₹123 Cr
Expenses ₹106 Cr₹97 Cr₹89 Cr₹99 Cr₹98 Cr
Operating Profit (Excl OI) ₹30 Cr₹27 Cr₹20 Cr₹20 Cr₹25 Cr
Other Income ₹5.12 Cr₹4.95 Cr₹4.31 Cr₹4.22 Cr₹3.45 Cr
Interest ₹0.37 Cr₹0.43 Cr₹0.47 Cr₹0.53 Cr₹0.39 Cr
Depreciation ₹2.26 Cr₹1.90 Cr₹2.04 Cr₹2.30 Cr₹1.35 Cr
Profit Before Tax ₹33 Cr₹30 Cr₹22 Cr₹21 Cr₹27 Cr
Profit After Tax ₹25 Cr₹22 Cr₹17 Cr₹15 Cr₹20 Cr
Consolidated Net Profit ₹25 Cr₹22 Cr₹17 Cr₹15 Cr₹20 Cr
Earnings Per Share (Rs)₹55.76₹48.58₹35.96₹32.40₹43.14
PAT Margin (%)17.9917.9815.1012.5116.14
ROE(%)20.5320.6618.4918.8928.54
ROCE(%)26.8026.8923.8325.7336.90
Total Debt/Equity(x)0.020.050.040.040.10

Key Financials

Market Cap : ₹ 326.9 Cr
Revenue (TTM) : ₹ 138.3 Cr
Net Profit(TTM) : ₹ 24.4 Cr
EPS (TTM) : ₹ 55.6
P/E (TTM) : 13.4

Industry Peers & Returns1W1M1Y
JENBURKT PHARMACEUTICALS 1.1% 6.3% 9.1%
SUN PHARMACEUTICAL INDUSTRIES 1.1% -6.6% 56.7%
CIPLA 0.2% -4.4% 54.3%
DR REDDYS LABORATORIES 4.3% 2.6% 29.9%
ZYDUS LIFESCIENCES 2.2% -4.6% 86.6%
DIVIS LABORATORIES 4.8% 18.9% 23.9%
MANKIND PHARMA -1.4% 1.4% NA
TORRENT PHARMACEUTICALS -1.7% 3% 65.8%
LUPIN 4.1% 3% 131.2%


JENBURKT PHARMACEUTICALS Revenues
[BOM: 524731]

Y-o-Y

10.30 %

5 Yr CAGR

2.76 %

Years Revenues % Change
Mar2023 ₹137 Cr
10.30
Mar2022 ₹124 Cr
13.44
Mar2021 ₹109 Cr
-8.07
Mar2020 ₹119 Cr
-3.06
Mar2019 ₹123 Cr -


JENBURKT PHARMACEUTICALS Operating Profit
[BOM: 524731]

Y-o-Y

11.42 %

5 Yr CAGR

5.06 %

Years Operating Profit % Change
Mar2023 ₹30 Cr
11.42
Mar2022 ₹27 Cr
37.36
Mar2021 ₹20 Cr
0.50
Mar2020 ₹20 Cr
-20.79
Mar2019 ₹25 Cr -

Operating Margins
Y-o-Y

1.05 %

5 Yr CAGR

2.25 %

Years Operating Margin% % Change
Mar2023 22.21%
1.05
Mar2022 21.98%
21.10
Mar2021 18.15%
9.27
Mar2020 16.61%
-18.26
Mar2019 20.32% -

JENBURKT PHARMACEUTICALS Profit After Tax
[BOM: 524731]

Y-o-Y

10.36 %

5 Yr CAGR

5.59 %

Years Profit After Tax % Change
Mar2023 ₹25 Cr
10.36
Mar2022 ₹22 Cr
35.12
Mar2021 ₹17 Cr
10.98
Mar2020 ₹15 Cr
-24.89
Mar2019 ₹20 Cr -

PAT Margins
Y-o-Y

0.06 %

5 Yr CAGR

2.75 %

Years PAT Margin(%) % Change
Mar2023 17.99 %
0.06
Mar2022 17.98 %
19.07
Mar2021 15.1 %
20.70
Mar2020 12.51 %
-22.49
Mar2019 16.14 % -

JENBURKT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 524731]

Y-o-Y

14.78 %

5 Yr CAGR

6.63 %

Years EPS % Change
Mar2023 ₹56
14.78
Mar2022 ₹49
35.09
Mar2021 ₹36
10.99
Mar2020 ₹32
-24.90
Mar2019 ₹43 -

JENBURKT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 524731]

Y-o-Y

-0.33 %

5 Yr CAGR

-7.68 %

Years ROCE % Change
Mar2023 26.8%
-0.33
Mar2022 26.89%
12.84
Mar2021 23.83%
-7.38
Mar2020 25.73%
-30.27
Mar2019 36.9% -

JENBURKT PHARMACEUTICALS Share Price vs Sensex

Current Share Price : ₹743.1
Current MarketCap: ₹ 326.9 Cr
Updated EOD on :Apr 30,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
JENBURKT PHARMACEUTICALS

1.1%

6.3%

9.1%

SENSEX

1%

2.8%

23.9%

JENBURKT PHARMACEUTICALS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about JENBURKT PHARMACEUTICALS Financials


How the annual revenues of JENBURKT PHARMACEUTICALS have changed ?

The Revenues of JENBURKT PHARMACEUTICALS have increased by 10.30% YoY .

How the Earnings per Share (EPS) of JENBURKT PHARMACEUTICALS have changed?

The Earnings Per Share (EPS) of JENBURKT PHARMACEUTICALS has increased by 14.78 % YoY .